PMC4899403_01
Fragmented red cell had appeared in the peripheral blood and presented severe hemolytic anemia
40064_2016_2312_Fig1_HTML.jpg
PMC4899403_01_40064_2016_2312_Fig1_HTML.jpg
Fig1
Rapid elevation of tumor marker levels (CEA 3.9-23.0, CA15-3 9.0-38.7), as manifested by severe anemia, was noted 14 months later, and fragmented red cells emerged in the peripheral blood (Fig. 1).
Bone scintigraphy was revealed uptake in the spine, ribs, and pelvis, however, there was no clear exacerbation compared to before MAHA onset
40064_2016_2312_Fig2_HTML.jpg
PMC4899403_01_40064_2016_2312_Fig2_HTML.jpg
Fig2
Systemic examination with CT showed no evidence of visceral metastasis, and bone scintigraphy revealed slight inhomogeneous uptake in the spine, ribs, and pelvis (Fig. 2); however, there was no clear exacerbation compared to previous results.
Transition of Tumor marker was linked with the treatment effect. EC epirubicin + cyclophosphamide, LET letrozole, PTX paclitaxel
40064_2016_2312_Fig3_HTML.jpg
PMC4899403_01_40064_2016_2312_Fig3_HTML.jpg
Fig3
Therapeutic course and changes in tumor marker levels, red blood and platelet counts are shown in Figs. 3 and 4.
Transition of RBC and Plt counts was linked with the treatment effect. But in course of treatment, RBC transfusions were performed quite frequently. RBC red blood cell, Plt platelet
40064_2016_2312_Fig4_HTML.jpg
PMC4899403_01_40064_2016_2312_Fig4_HTML.jpg
Fig4
Therapeutic course and changes in tumor marker levels, red blood and platelet counts are shown in Figs. 3 and 4.